FilingReader Intelligence
Astellas reports strong U.S. sales for Izervay
July 9, 2025 at 11:39 PM UTC•By FilingReader AI
Astellas Pharma today announced preliminary sales figures for IZERVAY (avacincaptad pegol) in the U.S. market for the first quarter of fiscal year 2025. The company stated that sales reached JPY 15.9 billion/USD 110 million during the period from April 1 to June 30, 2025. IZERVAY is a treatment for Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA).
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
TSE:4503•Tokyo Stock Exchange
News Alerts
Get instant email alerts when Astellas Pharma publishes news
Free account required • Unsubscribe anytime